Navigation Links
Results of the AIDA STEMI MRI sub-study presented at TCT 2012
Date:10/25/2012

MIAMI, FL OCTOBER 25, 2012 A study confirmed no differences in various measures of heart damage, according to cardiac magnetic resonance (MRI) imaging, in patients receiving the anti-clotting medication abxicimab directly into the heart (intracoronary) compared to those receiving it intravenously (IV). The results of the AIDA STEMI MRI sub-study were presented today the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

The AIDA STEMI trial was a randomized, open-label, multicenter trial in 2,065 patients presenting with ST-elevation myocardial infarction (STEMI) comparing intracoronary (IC) versus intravenous (IV) abciximab during PCI with subsequent 12 hour intravenous infusion. Last year, researchers reported that the trial found that both methods yielded similar 90-day rates of all-cause mortality, recurrent heart attack or congestive heart failure.

Researchers enrolled 703 patients within the overall trial in a cardiac magnetic resonance imaging sub-study, one of the largest MRI sub-studies conducted in patients with STEMI. Cardiac MRI allows for a more sensitive investigation of the mechanistic and pathophysiological effects of STEMI therapies on myocardial damage and reperfusion injury.

Cardiac MRI was completed within four days after heart attack using a standardized protocol including edema imaging and late gadolinium enhancement. Researchers examined infarct size, myocardial salvage, microvascular obstruction and ventricular function to determine the potential benefits of intracoronary compared to intravenous application of abciximab.

The amount of myocardium at risk and final infarct size did not differ significantly between the IC versus the IV abciximab groups. Consequently, the myocardial salvage index was similar between the two groups. In further detailed analysis there were no differences in microvascular obstruction between both treatment groups.

"Results of this sub-study demonstrate that intracoronary as compared to intravenous abciximab did not result in a difference in myocardial damage or reperfusion injury," said lead investigator Holger Thiele, MD. Dr. Thiele is Co-Director of the University of Leipzig - Heart Center in Germany.

"These findings confirm similarities in the combined endpoint of death, reinfarction and congestive heart failure found between the two methods in the AIDA STEMI trial," Dr. Thiele said.

Dr. Thiele will present the AIDA STEMI MRI sub-study on Thursday October 25 at 12:30 PM EST in the Main Arena (Hall D) at the Miami Beach Convention Center.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the PC trial presented at TCT 2012
2. Results of the POSEIDON trial presented at TCT 2012
3. 1-year results of ADAPT-DES presented at TCT 2012
4. Comparison of Obesity Surgeries Turns Up Surprising Results
5. Results from study of Mead Johnsons Enfamil® Human Milk Fortifier Acidified Liquid published in Pediatrics
6. Missed Diagnoses in ICU Often Have Deadly Results: Review
7. Anti-clotting drugs yield similar results
8. Late-Night Cramming May Hurt School Test Results
9. New survey: Women want to SEE breast reconstruction results before cancer surgery
10. Weight-loss surgery results in positive changes in social life, medical conditions
11. Many Test Results Left Unread as Patients Leave Hospital: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... This Saturday, ... & magic, plus a very special performance by Alabama Symphony Orchestra musicians Yifan Zhou, ... their specialties, such as dim sum, and exhibitors offer a look at Chinese games, ...
(Date:1/24/2017)... ... January 24, 2017 , ... The results from the American ... particularly good news for prostate cancer patients: incidents of cancer is down as is ... report the cancer death rate has dropped from its peak of 215.1 in 1991 ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... officially unveiled its latest award-winning bottles, designed specifically to optimize the drinking experience ... Taza Agua is renowned for introducing the world’s first untouched bottled water purposed ...
(Date:1/24/2017)... ... 24, 2017 , ... “Choosing Wisdom-Solomon’s Proverbs Reclaimed”: an ... gossip, prostitution, adultery, anger, and common sense. , “Choosing Wisdom-Solomon’s Proverbs Reclaimed” ... David Coats. In September of 1983, they flew to Haiti to focus on ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... “The Octagon ... balance. “The Octagon of Spiritual Balances” is the creation of published author, Pastor Bernard ... Bernard J. Weathers holds a bachelor degree in religious education and a master degree ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... PUNE, India , January 24, 2017 /PRNewswire/ ... Market Research, titled, "Cold Chain Logistics Market by Application ... Frozen Dessert, Meat, Fish & Sea Food, Drugs & ... Forecasts, 2014-2022," projects that the global cold chain logistics ... growing at a CAGR of 16% (2016 to 2022). ...
(Date:1/24/2017)... , Jan. 24, 2017 Regeneron Pharmaceuticals, Inc. ... Public today recognized 40 finalists in the Regeneron Science ... and math competition for high school seniors. Finalists were ... of their research projects. The finalists will ... from March 9-15 to undergo a rigorous judging process ...
(Date:1/24/2017)... 24, 2017 Research and Markets has announced ... Trends - Product, Material - Forecast to 2025" report to ... ... a CAGR of around 5.4% over the next decade to reach ... trends that the market is witnessing include 3D medical printing is ...
Breaking Medicine Technology: